The California Department of Public Health has granted Immunovia Inc., the American subsidiary of Immunovia AB, a Clinical and Public Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test for their patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.368 SEK | -0.15% | -9.88% | -22.80% |
Feb. 21 | Transcript : Immunovia AB, 2023 Earnings Call, Feb 21, 2024 | |
Feb. 21 | Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-22.80% | 5.84M | |
-34.95% | 3.23B | |
+12.43% | 1.79B | |
-0.43% | 1.67B | |
+36.05% | 1.38B | |
-3.90% | 1.11B | |
-19.15% | 915M | |
-6.11% | 738M | |
-11.71% | 716M | |
+12.74% | 537M |
- Stock
- Equities
- Stock Immunovia AB - Nasdaq Stockholm
- News Immunovia AB
- Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test